Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi-institutional retrospective study
Renpei Kato(Iwate Medical University), Wataru Obara(Iwate Medical University), Shingo Hatakeyama(Hirosaki University), Tomonori Habuchi(Akita University), Akihiro Ito(Tohoku University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Kazuyuki Numakura(Akita University), Sei Naito(Yamagata University), Norihiko Tsuchiya(Yamagata University), Takahiro Kojima(Aichi Cancer Center), Hiroyuki Nishiyama(University of Tsukuba), Chikara Οhyama(Hirosaki University), Yoichi Arai(Japan Atomic Energy Agency), Yoshihide Kawasaki(Tohoku University), Shuya Kandori(University of Tsukuba), Yoshiyuki Kojima(Fukushima Medical University), Tomoyuki Koguchi(Fukushima Medical University)
Cited by 10
Related Papers
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603